04.11.26 -- Cell & Gene Best Of March

Tr1X Bio Co-founder and CEO David de Vries explains how moving Type 1 regulatory T Cell (Tr1) therapies into new indications reshapes every facet of first-in-human trial design.

AI-driven cell therapies depend on high-quality, well-structured data to accelerate discovery, development, and clinical success.

Consider your pathway. A lot happened last year on the supply-chain front. Your plans and expectations were based on those trends and experiences. Are you currently abiding by those analyses?

The FDA encourages patient experience data in drug labeling but often excludes it for low rigor. New guidelines should help sponsors meet strict methodological standards.

Learn how collaborative distribution models manage reimbursement hurdles and complex delivery requirements to ensure patient access and long-term commercial success.

Discover how scalable, cost-effective, and high-quality lentiviral vector manufacturing can accelerate both ex vivo and emerging in vivo CAR-T therapies.